Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKBA NASDAQ:AVDL NASDAQ:ETNB NASDAQ:WVE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$1.30+4.8%$1.11$0.82▼$4.08$348.74M0.233.99 million shs6.34 million shsAVDLAvadel Pharmaceuticals$21.39-1.1%$21.48$8.19▼$23.57$2.09B1.312.03 million shs35.02 million shsETNB89BIO$14.84$14.82$6.55▼$15.06$2.20B1.273.57 million shs55.65 million shsWVEWAVE Life Sciences$6.32+1.0%$6.36$5.02▼$21.73$1.22B-1.294.15 million shs3.00 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics0.00%+8.77%+32.58%-6.06%-65.60%AVDLAvadel Pharmaceuticals0.00%0.00%0.00%0.00%+139.66%ETNB89BIO0.00%0.00%0.00%0.00%+46.35%WVEWAVE Life Sciences0.00%+7.38%+9.25%-11.71%-10.19%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$1.30+4.8%$1.11$0.82▼$4.08$348.74M0.233.99 million shs6.34 million shsAVDLAvadel Pharmaceuticals$21.39-1.1%$21.48$8.19▼$23.57$2.09B1.312.03 million shs35.02 million shsETNB89BIO$14.84$14.82$6.55▼$15.06$2.20B1.273.57 million shs55.65 million shsWVEWAVE Life Sciences$6.32+1.0%$6.36$5.02▼$21.73$1.22B-1.294.15 million shs3.00 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics0.00%+8.77%+32.58%-6.06%-65.60%AVDLAvadel Pharmaceuticals0.00%0.00%0.00%0.00%+139.66%ETNB89BIO0.00%0.00%0.00%0.00%+46.35%WVEWAVE Life Sciences0.00%+7.38%+9.25%-11.71%-10.19%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKBAAkebia Therapeutics 2.20Hold$4.67258.97% UpsideAVDLAvadel Pharmaceuticals 2.00Hold$20.20-5.56% DownsideETNB89BIO 2.00Hold$18.1722.42% UpsideWVEWAVE Life Sciences 2.87Moderate Buy$26.41317.91% UpsideCurrent Analyst Ratings BreakdownLatest AKBA, WVE, AVDL, and ETNB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2026AKBAAkebia Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.006/11/2026WVEWAVE Life Sciences New Street ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$13.006/11/2026WVEWAVE Life Sciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/20/2026WVEWAVE Life Sciences Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$13.00 ➝ $14.005/19/2026WVEWAVE Life Sciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$18.00 ➝ $13.005/6/2026AKBAAkebia Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/6/2026AKBAAkebia Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/4/2026WVEWAVE Life Sciences CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $24.004/30/2026WVEWAVE Life Sciences Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$52.00 ➝ $43.004/29/2026WVEWAVE Life Sciences Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$50.00 ➝ $15.004/20/2026WVEWAVE Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 7/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKBAAkebia Therapeutics$236.20M1.48N/AN/A$0.12 per share10.83AVDLAvadel Pharmaceuticals$248.52M8.41N/AN/A$0.77 per share27.78ETNB89BION/AN/AN/AN/A$3.34 per shareN/AWVEWAVE Life Sciences$42.73M28.46N/AN/A$3.10 per share2.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKBAAkebia Therapeutics-$5.34M-$0.08N/AN/AN/A-8.83%-62.72%-5.66%8/6/2026 (Estimated)AVDLAvadel Pharmaceuticals-$48.83MN/AN/A356.50N/A-0.11%-0.33%-0.15%N/AETNB89BIO-$367.08M-$3.61N/AN/AN/AN/A-94.48%-80.92%N/AWVEWAVE Life Sciences-$204.38M-$1.06N/AN/AN/A-255.70%-56.76%-42.80%7/30/2026 (Estimated)Latest AKBA, WVE, AVDL, and ETNB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2026Q2 2026WVEWAVE Life Sciences-$0.31N/AN/AN/A$7.45 millionN/A5/7/2026Q1 2026AKBAAkebia Therapeutics-$0.01-$0.03-$0.02-$0.03$51.67 million$53.54 million4/29/2026Q1 2026WVEWAVE Life Sciences-$0.34-$0.13+$0.21-$0.13$8.45 million$38.25 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAKBAAkebia TherapeuticsN/AN/AN/AN/AN/AAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/AETNB89BION/AN/AN/AN/AN/AWVEWAVE Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKBAAkebia Therapeutics1.331.401.33AVDLAvadel PharmaceuticalsN/A2.762.37ETNB89BIO0.0715.1915.19WVEWAVE Life SciencesN/A11.2611.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKBAAkebia Therapeutics33.92%AVDLAvadel Pharmaceuticals69.19%ETNB89BION/AWVEWAVE Life Sciences89.73%Insider OwnershipCompanyInsider OwnershipAKBAAkebia Therapeutics4.30%AVDLAvadel Pharmaceuticals5.20%ETNB89BIO2.60%WVEWAVE Life Sciences24.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKBAAkebia Therapeutics430268.26 million256.72 millionOptionableAVDLAvadel Pharmaceuticals7097.66 million92.58 millionOptionableETNB89BIO40148.31 million144.45 millionOptionableWVEWAVE Life Sciences240192.40 million145.65 millionOptionableAKBA, WVE, AVDL, and ETNB HeadlinesRecent News About These CompaniesDoes Wave Life Sciences (WVE) Have the Potential to Rally 294.66% as Wall Street Analysts Expect?July 1, 2026 | zacks.comWave Life Sciences (WVE) Initiates Multidose Phase 2a for INLIGHTTM TrialJune 30, 2026 | insidermonkey.comWave Life Sciences Shareholders Approve Redomiciliation SchemeJune 26, 2026 | tipranks.comWave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic DiseasesJune 24, 2026 | globenewswire.comWave Life Sciences (WVE) Upgraded to Buy: Here's WhyJune 16, 2026 | zacks.comIs Wave Life Sciences Ltd. (WVE) A Good Stock To Buy Now?June 13, 2026 | insidermonkey.comMizuho Securities Remains a Buy on Wave Life Sciences (WVE)June 13, 2026 | theglobeandmail.comIs Wave Life Sciences Ltd. (WVE) A Good Stock To Buy Now?June 13, 2026 | finance.yahoo.comBillionaire Lee Ainslie’s 5 Stocks with Huge Upside PotentialJune 12, 2026 | insidermonkey.comInside Wells Fargo’s Take on Wave Life Sciences Ltd (WVE) StockJune 12, 2026 | insidermonkey.comWave Life Sciences Ltd. (WVE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.comWave Life Sciences to Present at Upcoming Investor ConferencesJune 1, 2026 | globenewswire.comThis $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First QuarterMay 31, 2026 | fool.comAnalysts Are Bullish on Top Healthcare Stocks: Wave Life Sciences (WVE), Boston Scientific (BSX)May 29, 2026 | theglobeandmail.comWave Life Sciences Ltd. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their LossesMay 27, 2026 | globenewswire.comShould WVE-006’s RNA-Editing AAT Data Shift the Risk-Reward Calculus for Wave Life Sciences (WVE) Investors?May 25, 2026 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Wave Life Sciences (WVE), Gossamer Bio (GOSS) and Cullinan Management (CGEM)May 21, 2026 | theglobeandmail.comWave Life Sciences: 'Strong Buy' On DMD NDA Filing WVE-N531 And Released AATD DataMay 20, 2026 | seekingalpha.comWVE stock edges up after positive early data for rare disease drugMay 20, 2026 | msn.comBeam one-ups Wave as both show promise of genetic editing for AATDMay 20, 2026 | biospace.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAKBA, WVE, AVDL, and ETNB Company DescriptionsAkebia Therapeutics NASDAQ:AKBA$1.30 +0.06 (+4.84%) Closing price 04:00 PM EasternExtended Trading$1.30 +0.00 (+0.38%) As of 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Avadel Pharmaceuticals NASDAQ:AVDLAvadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.89BIO NASDAQ:ETNB89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.WAVE Life Sciences NASDAQ:WVE$6.32 +0.06 (+0.96%) Closing price 04:00 PM EasternExtended Trading$6.34 +0.02 (+0.40%) As of 06:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Flash Crash or Cash? The AI Hardware Reset Investors Can’t Ignore KBR Insiders Are Buying While the Market Misreads Its Spinoff Doug Casey Calls AI a Super Bubble, Bets on Energy, Gold Miners and Grains Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term Investors This Edge AI Stock Just Got a Huge Vote of Confidence From Wall Street AI Is Selling Off, But These 5 Stocks Could Benefit Next MarketBeat Week in Review – 06/29 - 07/03 Analysts Just Raised Price Targets On These 3 Semiconductor Equipment Stocks Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
